Skip to main content

Table 2 Safety profiles

From: Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

  n = 21 Percent
Dose-limiting toxicity (DLT) 0 0
Severe adverse events (SAE) 1 4.8
 Death (due to progressive disease) 1 4.8
Grade 3 or higher toxicity 2 9.5
 Blood system disorders 1 4.8
 Laboratory abnormalities 1 4.8